## Paul Gregorevic

## List of Publications by Citations

Source: https://exaly.com/author-pdf/5945789/paul-gregorevic-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

6,777 81 45 124 h-index g-index citations papers 8.2 7,836 132 5.43 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
124	Systemic delivery of genes to striated muscles using adeno-associated viral vectors. <i>Nature Medicine</i> , <b>2004</b> , 10, 828-34	50.5	519
123	Suppression of microRNA-29 expression by TGF-II promotes collagen expression and renal fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2012</b> , 23, 252-65	12.7	385
122	Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 17615-20	11.5	330
121	Extracellular Vesicles Provide a Means for Tissue Crosstalk during Exercise. <i>Cell Metabolism</i> , <b>2018</b> , 27, 237-251.e4	24.6	257
120	rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. <i>Nature Medicine</i> , <b>2006</b> , 12, 787-9	50.5	248
119	Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E8372-E8381	11.5	239
118	TGF-beta regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 13805-14	5.4	202
117	Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. <i>Molecular Therapy</i> , <b>2004</b> , 10, 671-8	11.7	195
116	Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. <i>Molecular Therapy</i> , <b>2007</b> , 15, 1160-6	11.7	192
115	miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. <i>Clinical Science</i> , <b>2015</b> , 129, 1237-49	6.5	161
114	Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. <i>Molecular Therapy</i> , <b>2007</b> , 15, 320-9	11.7	142
113	Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. <i>Journal of Cell Biology</i> , <b>2012</b> , 197, 997-1008	7.3	133
112	Elevated expression of activins promotes muscle wasting and cachexia. FASEB Journal, 2014, 28, 1711-	<b>23</b> 5.9	130
111	The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. <i>Journal of Cell Biology</i> , <b>2013</b> , 203, 345-57	7.3	128
110	Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. <i>Human Gene Therapy</i> , <b>2007</b> , 18, 18-26	4.8	119
109	TGFland BMP signaling in skeletal muscle: potential significance for muscle-related disease. <i>Trends in Endocrinology and Metabolism</i> , <b>2014</b> , 25, 464-71	8.8	111
108	Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. <i>Molecular Therapy</i> , <b>2007</b> , 15, 1086-92	11.7	110

## (2013-2002)

107	Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 2263-72	5.8	97
106	Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. <i>Molecular Therapy</i> , <b>2008</b> , 16, 657-64	11.7	96
105	Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. <i>Molecular Therapy</i> , <b>2008</b> , 16, 1539-45	11.7	93
104	Phosphoinositide 3-kinase p110ls a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 523-34	7.6	89
103	ACTN3 genotype influences muscle performance through the regulation of calcineurin signaling. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 4255-63	15.9	84
102	Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival. <i>Cell</i> , <b>2015</b> , 162, 1365-78	56.2	82
101	Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats. <i>Journal of Physiology</i> , <b>2004</b> , 555, 175-88	3.9	82
100	The Hippo pathway effector YAP is a critical regulator of skeletal muscle fibre size. <i>Nature Communications</i> , <b>2015</b> , 6, 6048	17.4	81
99	Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2007</b> , 1772, 243-62	6.9	79
98	In vivo and in vitro correction of the mdx dystrophin gene nonsense mutation by short-fragment homologous replacement. <i>Human Gene Therapy</i> , <b>2001</b> , 12, 629-42	4.8	79
97	Erratum to Efficient Transduction of Skeletal Muscle Using Vectors Based on Adeno-associated Virus Serotype 6\(\textit{Implication}\) Molecular Therapy, <b>2009</b> , 17, 1482	11.7	78
96	Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. <i>Molecular Therapy</i> , <b>2011</b> , 19, 36-45	11.7	74
95	Beta2-adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury. <i>Journal of Applied Physiology</i> , <b>2004</b> , 96, 1385-92	3.7	74
94	IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice. <i>Neuromuscular Disorders</i> , <b>2001</b> , 11, 260-8	2.9	73
93	Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. <i>Molecular Therapy</i> , <b>2006</b> , 13, 241-9	11.7	71
92	The calcineurin signal transduction pathway is essential for successful muscle regeneration in mdx dystrophic mice. <i>Acta Neuropathologica</i> , <b>2004</b> , 107, 299-310	14.3	68
91	Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice. <i>PLoS ONE</i> , <b>2008</b> , 3, e3387	3.7	67
90	miR-206 represses hypertrophy of myogenic cells but not muscle fibers via inhibition of HDAC4. <i>PLoS ONE</i> , <b>2013</b> , 8, e73589	3.7	63

89	Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. <i>FASEB Journal</i> , <b>2014</b> , 28, 5097-110	0.9	61
88	Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery. <i>Molecular Therapy</i> , <b>2005</b> , 12, 441-50	11.7	60
87	Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy. <i>PLoS ONE</i> , <b>2014</b> , 9, e90337	3.7	58
86	Beta 2-agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2002</b> , 283, R1386-94	3.2	56
85	Specific targeting of TGF-Ifamily ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E5266-E5275	11.5	54
84	Hyperbaric oxygen modulates antioxidant enzyme activity in rat skeletal muscles. <i>European Journal of Applied Physiology</i> , <b>2001</b> , 86, 24-7	3.4	52
83	Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression. <i>Molecular Therapy</i> , <b>2010</b> , 18, 206-13	11.7	49
82	Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. <i>American Journal of Pathology</i> , <b>2005</b> , 166, 1131-41	5.8	49
81	Disruption of the Class IIa HDAC Corepressor Complex Increases Energy Expenditure and Lipid Oxidation. <i>Cell Reports</i> , <b>2016</b> , 16, 2802-2810	10.6	48
80	Activin signaling regulates Sertoli cell differentiation and function. <i>Endocrinology</i> , <b>2012</b> , 153, 6065-77	4.8	48
79	Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 348ra98	17.5	45
78	Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice. <i>Muscle and Nerve</i> , <b>2004</b> , 30, 295-304	3.4	44
77	Differential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia. <i>Cancer Research</i> , <b>2016</b> , 76, 5372-82	10.1	43
76	rAAV6-microdystrophin rescues aberrant Golgi complex organization in mdx skeletal muscles. <i>Traffic</i> , <b>2007</b> , 8, 1424-39	5.7	43
75	Development of novel activin-targeted therapeutics. <i>Molecular Therapy</i> , <b>2015</b> , 23, 434-44	11.7	40
74	Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. <i>Human Molecular Genetics</i> , <b>2007</b> , 16, 2105-13	5.6	40
73	Onset of experimental severe cardiac fibrosis is mediated by overexpression of Angiotensin-converting enzyme 2. <i>Hypertension</i> , <b>2009</b> , 53, 694-700	8.5	36
72	Leukemia inhibitory factor ameliorates muscle fiber degeneration in the mdx mouse. <i>Muscle and Nerve</i> , <b>2000</b> , 23, 1700-5	3.4	36

## (2000-2009)

<ul><li>34</li><li>33</li><li>33</li><li>30</li><li>29</li><li>29</li></ul>
33 30 29
29
29
29
27
26
24
24
23
23
23
21
21
20

53	Gene therapy for muscular dystrophy? a review of promising progress. <i>Expert Opinion on Biological Therapy</i> , <b>2003</b> , 3, 803-814	5.4	20
52	Generation of a specific activin antagonist by modification of the activin A propeptide. <i>Endocrinology</i> , <b>2011</b> , 152, 3758-68	4.8	19
51	Induction of experimental autoimmune orchitis in mice: responses to elevated circulating levels of the activin-binding protein, follistatin. <i>Reproduction</i> , <b>2017</b> , 154, 293-305	3.8	16
50	Specific force of the rat extraocular muscles, levator and superior rectus, measured in situ. <i>Journal of Neurophysiology</i> , <b>2001</b> , 85, 1027-32	3.2	16
49	Using AAV vectors expressing the <b>2</b> -adrenoceptor or associated G[proteins to modulate skeletal muscle mass and muscle fibre size. <i>Scientific Reports</i> , <b>2016</b> , 6, 23042	4.9	16
48	Glucose-6-phosphate dehydrogenase contributes to the regulation of glucose uptake in skeletal muscle. <i>Molecular Metabolism</i> , <b>2016</b> , 5, 1083-1091	8.8	15
47	Viral vectors for gene transfer to striated muscle. <i>Current Opinion in Molecular Therapeutics</i> , <b>2004</b> , 6, 491-8		15
46	Abnormal mitochondrial L-arginine transport contributes to the pathogenesis of heart failure and rexoygenation injury. <i>PLoS ONE</i> , <b>2014</b> , 9, e104643	3.7	14
45	Gene therapy targeting cardiac phosphoinositide 3-kinase (p110Nattenuates cardiac remodeling in type 2 diabetes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2020</b> , 318, H840-l	H8 <u>52</u>	13
44	Skeletal muscle-specific overexpression of heat shock protein 72 improves skeletal muscle insulin-stimulated glucose uptake but does not alter whole body metabolism. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1928-1936	6.7	13
43	Modulating myosin restores muscle function in a mouse model of nemaline myopathy. <i>Annals of Neurology</i> , <b>2016</b> , 79, 717-725	9.4	13
42	Integrated Glycoproteomics Identifies a Role of N-Glycosylation and Galectin-1 on Myogenesis and Muscle Development. <i>Molecular and Cellular Proteomics</i> , <b>2020</b> , 20, 100030	7.6	13
41	Generation of MicroRNA-34 Sponges and Tough Decoys for the Heart: Developments and Challenges. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1090	5.6	13
40	Forced expression of muscle specific kinase slows postsynaptic acetylcholine receptor loss in a mouse model of MuSK myasthenia gravis. <i>Physiological Reports</i> , <b>2015</b> , 3, e12658	2.6	12
39	Endurance training adaptations modulate the redox-force relationship of rat isolated slow-twitch skeletal muscles. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2003</b> , 30, 77-81	3	12
38	Hyperbaric oxygen increases the contractile function of regenerating rat slow muscles. <i>Medicine and Science in Sports and Exercise</i> , <b>2002</b> , 34, 630-6	1.2	11
37	Functional properties of regenerating skeletal muscle following LIF administration. <i>Muscle and Nerve</i> , <b>2000</b> , 23, 1586-8	3.4	11
36	Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart. <i>Cardiovascular Research</i> , <b>2021</b> ,	9.9	11

35	Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	11
34	Gene delivery of medium chain acyl-coenzyme A dehydrogenase induces physiological cardiac hypertrophy and protects against pathological remodelling. <i>Clinical Science</i> , <b>2018</b> , 132, 381-397	6.5	10
33	Phosphorylation within the cysteine-rich region of dystrophin enhances its association with Edystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 6697-711	5.6	10
32	Hyperbaric oxygen increases the contractile function of regenerating rat slow muscles. <i>Medicine and Science in Sports and Exercise</i> , <b>2002</b> , 34, 630-636	1.2	10
31	Skeletal muscle-specific overexpression of IGFBP-2 promotes a slower muscle phenotype in healthy but not dystrophic mdx mice and does not affect the dystrophic pathology. <i>Growth Hormone and IGF Research</i> , <b>2016</b> , 30-31, 1-10	2	10
30	The Effect of ACTN3 Gene Doping on Skeletal Muscle Performance. <i>American Journal of Human Genetics</i> , <b>2018</b> , 102, 845-857	11	9
29	Activin A-Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice. <i>Endocrinology</i> , <b>2019</b> , 160, 2417-2426	4.8	8
28	Functional Endrenoceptors are important for early muscle regeneration in mice through effects on myoblast proliferation and differentiation. <i>PLoS ONE</i> , <b>2014</b> , 9, e101379	3.7	8
27	Transduction of skeletal muscles with common reporter genes can promote muscle fiber degeneration and inflammation. <i>PLoS ONE</i> , <b>2012</b> , 7, e51627	3.7	8
26	Preclinical studies for gene therapy of Duchenne muscular dystrophy. <i>Journal of Child Neurology</i> , <b>2010</b> , 25, 1149-57	2.5	8
25	The atypical 'b' splice variant of phospholipase CII promotes cardiac contractile dysfunction. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2015</b> , 84, 95-103	5.8	7
24	Muscle specific kinase protects dystrophic mdx mouse muscles from eccentric contraction-induced loss of force-producing capacity. <i>Journal of Physiology</i> , <b>2019</b> , 597, 4831-4850	3.9	7
23	Sex-Specific Control of Human Heart Maturation by the Progesterone Receptor. <i>Circulation</i> , <b>2021</b> , 143, 1614-1628	16.7	6
22	The E3 ligase MARCH5 is a PPARItarget gene that regulates mitochondria and metabolism in adipocytes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2019</b> , 316, E293-E304	6	5
21	Dynamic Changes to the Skeletal Muscle Proteome and Ubiquitinome Induced by the E3 Ligase, ASB2[]Molecular and Cellular Proteomics, <b>2021</b> , 20, 100050	7.6	4
20	Intravascular Follistatin gene delivery improves glycemic control in a mouse model of type 2 diabetes. <i>FASEB Journal</i> , <b>2020</b> , 34, 5697-5714	0.9	3
19	Bone Morphogenetic Protein 7 Gene Delivery Improves Cardiac Structure and Function in a Murine Model of Diabetic Cardiomyopathy. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 719290	5.6	3
18	TMEPAI/PMEPA1 Is a Positive Regulator of Skeletal Muscle Mass. Frontiers in Physiology, <b>2020</b> , 11, 560.	<b>22</b> <u>5</u> 6	3

17	Phosphorylation of ERK and dystrophin S3059 protects against inflammation-associated C2C12 myotube atrophy. <i>American Journal of Physiology - Cell Physiology</i> , <b>2021</b> , 320, C956-C965	5.4	3
16	Yap regulates skeletal muscle fatty acid oxidation and adiposity in metabolic disease. <i>Nature Communications</i> , <b>2021</b> , 12, 2887	17.4	3
15	Loss of the long non-coding RNA OIP5-AS1 exacerbates heart failure in a sex-specific manner. <i>IScience</i> , <b>2021</b> , 24, 102537	6.1	3
14	The regulation of polyamine pathway proteins in models of skeletal muscle hypertrophy and atrophy: a potential role for mTORC1. <i>American Journal of Physiology - Cell Physiology</i> , <b>2021</b> , 320, C987-	€ <del>99</del> 9	3
13	Site-Specific Glycation and Chemo-enzymatic Antibody Sortagging for the Retargeting of rAAV6 to Inflamed Endothelium. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2019</b> , 14, 261-269	6.4	2
12	Lentiviral transduction of rat Sertoli cells as a means to modify gene expression. <i>Spermatogenesis</i> , <b>2012</b> , 2, 279-284		2
11	Functional enhancement of skeletal muscle by gene transfer. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , <b>2005</b> , 16, 875-87, vii-viii	2.3	2
10	Molecular characterization of latent GDF8 reveals mechanisms of activation		2
9	genotype influences skeletal muscle mass regulation and response to dexamethasone. <i>Science Advances</i> , <b>2021</b> , 7,	14.3	2
8	Mechanisms involved in follistatin-induced hypertrophy and increased insulin action in skeletal muscle		1
7	Mechanisms involved in follistatin-induced hypertrophy and increased insulin action in skeletal muscle  The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. <i>Journal of Experimental Medicine</i> , <b>2013</b> , 210, 21012OIA54	16.6	1
	The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. <i>Journal of</i>	16.6 3.9	
7	The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. <i>Journal of Experimental Medicine</i> , <b>2013</b> , 210, 21012OIA54  Bone Geometry Is Altered by Follistatin-Induced Muscle Growth in Young Adult Male Mice. <i>JBMR</i>		1
7	The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. <i>Journal of Experimental Medicine</i> , <b>2013</b> , 210, 21012OIA54  Bone Geometry Is Altered by Follistatin-Induced Muscle Growth in Young Adult Male Mice. <i>JBMR Plus</i> , <b>2021</b> , 5, e10477  Tissue-specific expression of Cas9 has no impact on whole-body metabolism in four transgenic	3.9	1
7 6 5	The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. <i>Journal of Experimental Medicine</i> , <b>2013</b> , 210, 21012OIA54  Bone Geometry Is Altered by Follistatin-Induced Muscle Growth in Young Adult Male Mice. <i>JBMR Plus</i> , <b>2021</b> , 5, e10477  Tissue-specific expression of Cas9 has no impact on whole-body metabolism in four transgenic mouse lines. <i>Molecular Metabolism</i> , <b>2021</b> , 53, 101292	3.9	1

Therapeutic Gene Transfer to Skeletal Muscle123-128